Novartis’ ofatumumab meets primary endpoints in two phase 3 RMS trials

Novartis’ ofatumumab meets primary endpoints in two phase 3 RMS trials

Submitted by admin on September 2, 2019 - 12:24pm
Source: 
Pharmaceutical Business Review
News Tags: 
Novartis
ofatumumab
OMB157
Aubagio
clinical trials
relapsing multiple sclerosis
Headline: 
Novartis’ ofatumumab meets primary endpoints in two phase 3 RMS trials
snippet: 

Novartis said that its human anti-CD20 monoclonal antibody ofatumumab (OMB157) showed superiority over Aubagio (teriflunomide) in two phase 3 trials in patients with relapsing forms of multiple sclerosis (RMS).

Do Not Allow Advertisers to Use My Personal information